517 related articles for article (PubMed ID: 15761464)
1. Origins and molecular pathology of ovarian cancer.
Bell DA
Mod Pathol; 2005 Feb; 18 Suppl 2():S19-32. PubMed ID: 15761464
[TBL] [Abstract][Full Text] [Related]
2. [Molecular carcinogenesis of ovarian carcinoma].
Diebold J
Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathology of epithelial ovarian cancer.
Christie M; Oehler MK
J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
[TBL] [Abstract][Full Text] [Related]
4. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
5. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
8. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
9. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
10. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
11. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
12. TP53 and ovarian cancer.
Schuijer M; Berns EM
Hum Mutat; 2003 Mar; 21(3):285-91. PubMed ID: 12619114
[TBL] [Abstract][Full Text] [Related]
13. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas.
Sarrió D; Moreno-Bueno G; Sánchez-Estévez C; Bañón-Rodríguez I; Hernández-Cortés G; Hardisson D; Palacios J
Hum Pathol; 2006 Aug; 37(8):1042-9. PubMed ID: 16867867
[TBL] [Abstract][Full Text] [Related]
14. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
15. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
18. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.
Russell SE; McCluggage WG
J Pathol; 2004 Jun; 203(2):617-9. PubMed ID: 15141374
[TBL] [Abstract][Full Text] [Related]
19. My approach to and thoughts on the typing of ovarian carcinomas.
McCluggage WG
J Clin Pathol; 2008 Feb; 61(2):152-63. PubMed ID: 17704261
[TBL] [Abstract][Full Text] [Related]
20. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
